ArticleCartilage2026
A Metal-Polyphenol Complex Eliminates Chondrocytic ROS to Ameliorate Osteoarthritis.
Article in Cartilage, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOsteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage degradation and chronic inflammation. Currently, none of the available treatments can effectively halt or reverse the irreversible loss of extracellular matrix. In this study, we developed a hyaluronic acid (HA)-modified metal-phenolic network (MPN) nanostructure (FPB-HA) to enable targeted antioxidant delivery and microenvironmental regulation for OA therapy.
designThe coordinated chelating effect between Prussian blue nanoparticles (PBNPs) and ferulic acid (FA) was utilized to construct the MPN framework, followed by surface modification with HA. The biocompatibility, ROS-scavenging capacity, and anti-inflammatory effects of FPB-HA were evaluated in ATDC5 chondrocytes. The therapeutic efficacy was further assessed in an anterior cruciate ligament transection (ACLT)-induced OA mouse model through histological analysis and OARSI scoring.
resultsFPB-HA exhibited excellent biocompatibility and potent ROS-scavenging activity in vitro. Western blot analysis demonstrated that FPB-HA significantly upregulated anabolic markers (SOX9, COL2, ACAN) while suppressing catabolic proteases (MMP13, ADAMTS4, ADAMTS5). In vivo, FPB-HA treatment markedly attenuated cartilage degeneration, reduced proteoglycan loss, and improved OARSI scores compared to the untreated OA group.
conclusionsThe MPN-based FPB-HA nanocomposite effectively alleviates oxidative stress, suppresses catabolic signaling, and reinstates anabolic matrix synthesis in chondrocytes, providing a promising disease-modifying therapeutic strategy for early-stage OA.
Indexed as
Identifiers
42849031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.